NTAP

NetApp Extends Its Storage Leadership and Innovation at INSIGHT 2023 with the Only Unified Data Storage Across On-premises and Public Cloud

Retrieved on: 
Tuesday, October 24, 2023

Today, NetApp extends the definition of unified data storage to an entire architecture that enables file, block, and object workloads.

Key Points: 
  • Today, NetApp extends the definition of unified data storage to an entire architecture that enables file, block, and object workloads.
  • Unified data storage provides a common storage operating system that spans multiple on-premises storage offerings and every major public cloud, unified by a common API set and single control plane.
  • This includes the leading unified all-Flash storage, NetApp AFF, the new block-optimized all-Flash storage, NetApp ASA, and the only first-party, cloud-native storage solutions running on all of the three largest public clouds with Amazon FSx for NetApp ONTAP, Microsoft Azure NetApp Files, and Google Cloud NetApp Volumes.
  • To better serve these customers and the overall block storage market, NetApp introduced the NetApp All-Flash SAN Array (ASA) earlier this year.

NetApp Advances the State of AI & Secure Infrastructure at INSIGHT 2023

Retrieved on: 
Tuesday, October 24, 2023

Yesterday at NetApp INSIGHT 2023, Google Cloud CEO Thomas Kurian spoke to the ongoing innovation and partnership between NetApp and his company, highlighting the August 2023 introduction of Google Cloud NetApp Volumes.

Key Points: 
  • Yesterday at NetApp INSIGHT 2023, Google Cloud CEO Thomas Kurian spoke to the ongoing innovation and partnership between NetApp and his company, highlighting the August 2023 introduction of Google Cloud NetApp Volumes.
  • Today, NetApp and Google are announcing support for Google Cloud’s Vertex AI with Google Cloud NetApp Volumes to support hybrid Generative AI applications.
  • Today, NetApp extended its Ransomware Recovery Guarantee is available for all on-premises NetApp ONTAP-based storage systems, including NetApp AFF, ASA and FAS.
  • NetApp can provide a single solution for DR from on premises to the cloud, minimizing the cost of providing standby DR infrastructure.

NetApp’s 2023 Data Complexity Report Reveals Urgent Need for Unified Data Storage

Retrieved on: 
Wednesday, October 18, 2023

NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today released the 2023 Data Complexity Report , a global report that explores companies’ growing needs for unified data storage.

Key Points: 
  • NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today released the 2023 Data Complexity Report , a global report that explores companies’ growing needs for unified data storage.
  • “The Data Complexity Report underscores that amidst this complexity, innovative cloud-enabled Flash storage solutions are needed to address the evolving demands of AI, enhance efficiency, and bolster resilience against the escalating cyber threats within the data ecosystem.”
    Migration to the cloud hasn’t been a linear journey for many businesses, according to the report.
  • According to the study, data security (57 percent), data integration (50 percent), and talent scarcity (45 percent) persist as barriers.
  • Forty percent of respondents ranked security threats and data privacy among the top causes of complexity in their storage infrastructure.

NetApp Hosts Technology Sessions at 2023 INSIGHT Conference in Las Vegas, Nevada

Retrieved on: 
Tuesday, October 17, 2023

NetApp (NASDAQ: NTAP) will hold their 2023 INSIGHT™ customer conference in Las Vegas, Nevada on October 23 – 25, 2023.

Key Points: 
  • NetApp (NASDAQ: NTAP) will hold their 2023 INSIGHT™ customer conference in Las Vegas, Nevada on October 23 – 25, 2023.
  • Furthermore, NetApp will also host a keynote session of mainstage headliners from 3:00 p.m. – 4:30 p.m. Pacific Time which will include special tech luminaries, industry leaders and entertainment icons.
  • Live video webcasts of both events will be available at http://investors.netapp.com .
  • A webcast replay of the events will be available at http://investors.netapp.com approximately 24 hours after the event.

NetApp and Equinix Deliver Industry’s Most Comprehensive Bare Metal-as-a-Service Solution for Cloud Adjacent Experience

Retrieved on: 
Monday, October 16, 2023

NetApp® (NASDAQ: NTAP), a global cloud-led, data centric software company, today announced their new joint Bare-Metal-as-a-Service (BMaaS) solution, NetApp Storage on Equinix Metal.

Key Points: 
  • NetApp® (NASDAQ: NTAP), a global cloud-led, data centric software company, today announced their new joint Bare-Metal-as-a-Service (BMaaS) solution, NetApp Storage on Equinix Metal.
  • NetApp Storage on Equinix Metal provides customers with a full stack of compute, networking and storage infrastructure with low-latency interconnection to all major public clouds.
  • NetApp can now deliver the entire stack in Equinix IBX data centers outfitted with Equinix Metal.
  • On Equinix’s global dedicated bare metal equipment, users have full access to NetApp cloud services such as Cloud Volumes ONTAP.

FDA Grants ExThera Multiple Breakthrough Device Designations for its Seraph® 100 Filter

Retrieved on: 
Tuesday, October 3, 2023

ExThera Medical Corporation, a healthcare company developing and manufacturing extracorporeal pathogen technologies, announces that it has received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA), for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100).

Key Points: 
  • ExThera Medical Corporation, a healthcare company developing and manufacturing extracorporeal pathogen technologies, announces that it has received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA), for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100).
  • The Seraph 100 is a patented blood filter containing a biomimetic surface, similar to that found in the human circulatory system that removes pathogens that could otherwise overwhelm a patient; a common source of severe/critical illness.
  • “In addition, a Breakthrough Device Designation allows for immediate coverage through Centers for Medicare and Medicaid Services (CMS) via New Technology Add-On Payment (NTAP).
  • Breakthrough Device Designations are an important addition to this ongoing activity, along with future pandemic preparedness.

Premia Spine Announces New Technology Add-On Payment for TOP™ System

Retrieved on: 
Monday, October 2, 2023

NORWALK, Conn., Oct. 2, 2023 /PRNewswire-PRWeb/ -- Premia Spine, an innovator in spine medical devices, announced the initiation of the Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment (NTAP) Program for the TOPS™ System. The payment, of up to an additional $11,375 beyond the standard DRG payment for the procedure, is available to all facilities who provide inpatient care to patients with spinal stenosis and spondylolisthesis. This is only the third time that CMS has granted an incentive payment to facilities for the use of any spinal implant.

Key Points: 
  • NORWALK, Conn., Oct. 2, 2023 /PRNewswire-PRWeb/ -- Premia Spine, an innovator in spine medical devices, announced the initiation of the Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment (NTAP) Program for the TOPS™ System.
  • This is only the third time that CMS has granted an incentive payment to facilities for the use of any spinal implant.
  • TOPS has proven its ability to provide both clinical excellence and healthcare economic advantage to patients, providers, and payers," says Ron Sacher, CEO of Premia Spine.
  • Ron Sacher , CEO of Premia Spine commented, "We are honored by the recognition of CMS.

Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)

Retrieved on: 
Monday, October 2, 2023

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).

Key Points: 
  • Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).
  • “These two important milestones will help facilitate access to this innovative treatment option in both inpatient and outpatient settings.
  • Last year, Melinta acquired the exclusive rights to commercialize REZZAYO in the U.S. from Cidara Therapeutics.
  • “This is another opportunity for Melinta to deliver on our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses.”

MCRA Assists Ceribell with Obtaining FDA Breakthrough Device Designation, FDA Marketing Authorization, and CMS NTAP Reimbursement for ClarityPro Device

Retrieved on: 
Monday, September 25, 2023

MCRA's Neurology and Digital Health regulatory teams played a key role in successfully achieving both the Breakthrough Device Designation and clearance of the 510(k) premarket notification for Ceribell's ClarityPro device.

Key Points: 
  • MCRA's Neurology and Digital Health regulatory teams played a key role in successfully achieving both the Breakthrough Device Designation and clearance of the 510(k) premarket notification for Ceribell's ClarityPro device.
  • In addition, MCRA's Reimbursement, Health Economics, and Market Access team provided Ceribell with valuable insights, analyses, and strategic guidance on the NTAP application.
  • Raymond Woo, CTO of Ceribell said, "Ceribell feels extremely fortunate to have partnered with MCRA on ClarityPro as well as other projects.
  • The FDA Breakthrough Device program is itself relatively new, and the CMS NTAP alternative pathway for breakthrough devices is an even more recent development.

Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

Retrieved on: 
Thursday, September 7, 2023

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the DETOUR System, an FDA-designated Breakthrough Device, as part of its Fiscal Year 2024 Hospital Inpatient Prospective Payment System.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the DETOUR System, an FDA-designated Breakthrough Device, as part of its Fiscal Year 2024 Hospital Inpatient Prospective Payment System.
  • NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries.
  • Beginning October 1, 2023, CMS will provide hospitals with additional device reimbursement when the DETOUR System is used for eligible cases in the hospital inpatient setting.
  • “Receiving the NTAP designation is a testament to the transformative potential of the DETOUR System in treating complex PAD.